Shopping Cart

No products in the cart.

The Society
Conference and Events
- Conferences
  
  Annual Conference 2025
  
  Abstract Submission 2025
  
  Programme 2025
  
  Congress Information 2025
  
  Register for the Conference ⟶
  
  Join us at the forefront of innovation and collaboration! Secure your spot at the 2025 conference today. Don’t miss this opportunity to connect with industry leaders, engage in insightful discussions, and expand your professional network.
  
  Submit an Abstract 2025 (Opening June 15th)
  Are you ready to share your groundbreaking research and innovative ideas with leading experts in the field? We invite you to submit your abstract for the 2025 conference.
Resources
- Resources
  
  Latest ↗
  
  Cachexia ↗
  
  Sarcopenia ↗
  
  Muscle Wasting ↗
  
  Frailty ↗
  
  Ageing ↗
  
  Nutrition ↗
  
  From the Literature ↗
  
  Cancer Cachexia
  
  Exercise ↗
  
  Videos ↗
  
  Explore our Publications Digest ⟶
  
  Staying informed on the latest in cachexia, sarcopenia, and wasting disorders research is essential yet challenging. The SCWD Digest offers concise updates and expert insights into significant studies and developments.
  
  The Journal of Cachexia, Sarcopenia & Muscle ⟶
  The Journal of Cachexia, Sarcopenia and Muscle is a peer-reviewed international journal dedicated to publishing both research and clinical materials related to cachexia and sarcopenia from all fields of the life sciences.
Guidelines
Membership

Free

Safety

Frailty

Metformin and physical performance in older people with probable sarcopenia and physical prefrailty or frailty in England (MET-PREVENT): a double-blind, randomised, placebo-controlled trial.

Metformin has effects on multiple biological systems relevant to ageing and has been posited as a candidate therapy for sarcopenia and physical frailty. We aimed to test the efficacy and safety of metformin, a candidate geroprotector, to improve physical performance...

🗓️ 2025-03-24

Drug-related_side_effects_and_adverse_reactions / Healthy_aging / Metformin / Safety / Sarcopenia / therapeutics

Exercise

BIO101 in Sarcopenic Seniors at Risk of Mobility Disability: Results of a Double-Blind Randomised Interventional Phase 2b Trial.

Sarcopenia is a progressive muscle disorder that may lead to mobility disability. No pharmaceutical interventions are currently available, and treatment relies on physical exercise and nutrition. The aim of SARA-INT was to investigate whether BIO101 (20-hydroxyecdysone), an activator of the...

🗓️ 2025-04-01

📰 Publication: Journal Of Cachexia Sarcopenia And Muscle

cachexia / muscles / Safety / Sarcopenia / therapeutics / Walking_speed

Muscle

Novel oral compound Z526 mitigates cancer-associated cachexia via intervening NF-κB signaling and oxidative stress.

Cancer-associated cachexia (CAC) is a severe metabolic disorder syndrome mainly characterized by muscle and fat loss, which accounts for one-third of cancer-related deaths. No effective therapeutic approach that could fully reverse CAC is available. NF-κB signaling and oxidative stress play...

🗓️ 2024-04-08

📰 Publication: Genes & Diseases

cachexia / Cancer-associated_cachexia / muscles / Muscular_atrophy / neoplasms / Oxidative_stress / Safety / Stress,_physiological / therapeutics

Conferences

Register for the Conference ⟶

Submit an Abstract 2025 (Opening June 15th)

Resources

Explore our Publications Digest ⟶

The Journal of Cachexia, Sarcopenia & Muscle ⟶

Safety

Metformin and physical performance in older people with probable sarcopenia and physical prefrailty or frailty in England (MET-PREVENT): a double-blind, randomised, placebo-controlled trial.

BIO101 in Sarcopenic Seniors at Risk of Mobility Disability: Results of a Double-Blind Randomised Interventional Phase 2b Trial.

Novel oral compound Z526 mitigates cancer-associated cachexia via intervening NF-κB signaling and oxidative stress.

Subscribe to the SCWD Newsletter

Stay Informed with the Latest Updates and Exclusive Insights!

From Litterature

Non-profit organizations

Support